Topic: quadrivalent vaccine
A phase 3 study shows that Seqirus' MF59-adjuvanted quadrivalent flu vaccine provides better protection in those younger than two years old.
Just a month after winning a big government contract for pandemic flu preparedness, Protein Sciences has notched an FDA approval for its next flu vaccine offering.
This past season's flu vaccines posted one of the worst efficacy rates in recent memory. That's partly because the viral strains they contained weren't the ones that ended up circulating. But on top of that, GlaxoSmithKline has uncovered some other effectiveness problems of its own--and now it's recalling a quadrivalent jab in a move that affects 1.7 million doses.